Data Show Statistically Significant Improvements in Pain, Function and Tendon Structure in Appropriately Dosed Patients. READ MORE
10.25
MicroRNAs blaze into the clinic
After decades-long struggles with microRNA-based therapeutics, Regulus hits paydirt in the clinic and in the marketplace. Is it the beginning of a trend or a one-off?
CLICK TO DOWNLOAD ARTICLE
10.26.23
CAUSEWAY SECURES £8.75 MILLION INVESTMENT
Causeway is delighted to announce the completion of a £8.75 million investment. The round was led by Declan Doogan (our Executive Chairman) along with Scottish Investment Bank, MediqVentures, Lennox Capital and the University of Glasgow. This funding will allow us to continue TenoMiR®’s development for the treatment of tendinopathy, building on the positive trial data from our Phase 1b, which appeared safe and well tolerated. TenoMiR® also showed encouraging signs of efficacy- improving pain and function in patients with Lateral epicondylitis (tennis elbow). Strikingly, TenoMiR® also showed unprecedented improvement in tendon structure. A Phase 2 study in the USA, The Netherlands and the UK will begin recruiting in September 2023.